Ticagrelor Continue vs De Escalate Tool
Clinical assessment
Review bleeding and ischemic concerns after PCI. This decision aid does not replace individualized cardiology assessment.
Clinical context
After acute coronary syndrome (ACS), aspirin plus an oral P2Y12 inhibitor is the default dual antiplatelet therapy (DAPT) strategy for at least 12 months in patients who are not at high bleeding risk. Ticagrelor or prasugrel is generally preferred to clopidogrel after ACS PCI when suitable.
Alternative strategies can reduce bleeding in selected patients. The 2025 ACC/AHA ACS guideline states that de-escalation from ticagrelor or prasugrel to clopidogrel after 1 month may be reasonable in ACS patients undergoing PCI; in patients who have tolerated ticagrelor-based DAPT, transition to ticagrelor monotherapy at least 1 month after PCI is also a recommended bleeding-reduction strategy. These approaches are not interchangeable and require patient-specific review.
How to interpret this tool
- Do not use a simple count of the selected features as a validated bleeding-risk score.
- Recurrent ischemia or suspected stent thrombosis warrants prompt clinical evaluation rather than an automatic medication recommendation.
- De-escalation in the first 30 days after ACS is generally not recommended as a routine strategy.
- Consider formal ARC-HBR/PRECISE-DAPT assessment and the patient's ischemic risk, bleeding history, drug tolerance, concomitant anticoagulation, and preferences.
References
Clinical notes
Document key findings and keep a structured record for your own reference.
My notes
Review, edit, or remove notes saved in this browser.
Report an issue
Your feedback helps us improve the reliability and usability of this clinical tool.